{"gao_id": "GAO-17-64", "published": "2016-11-17T12:00:00Z", "released": "2016-11-17T07:00:00Z", "summary": "A 2012 outbreak of fungal meningitis raised concerns about state and federal oversight of drug compounding, which is the process of creating a drug tailored for an individual patient. To improve public safety, a 2013 law helped clarify FDA's authority to oversee this practice. We found that FDA and some states collect data on the number of drug compounders, but not the volume of compounded...", "title": "Drug Compounding: FDA Has Taken Steps to Implement Compounding Law, but Some States and Stakeholders Reported Challenges", "topics": ["Adverse events", "Health Care", "Food and drug law", "Physicians", "Prescription drugs", "Compliance oversight", "Laws and regulations", "Outsourcing", "Food and drug legislation", "Medicine", "Drugs", "Patient care", "Manufacturing practices", "Pharmacist"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-17-64", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-17-64-highlights.pdf"}, {"title": "Full Report (70 pages)", "url": "https://www.gao.gov/assets/gao-17-64.pdf"}, {"title": "Accessible PDF (70 pages)", "url": "https://www.gao.gov/assets/690/681876.pdf"}]}